Drug
Lupin S Pegfilgrastim
Lupin S Pegfilgrastim: highest development phase Post-Market, developed by Lupin. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Lupin
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lupin's Pegfilgrastim NCT03511378 | Post-Market | Breast Cancer |
Latest
No recent events.
Follow Lupin S Pegfilgrastim on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.